Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment with CTX-009 alone or in combination with CTX-471 will lead to enhanced tumor control and prolongation of overall survival of patients with recurrent glioblastoma. CTX-009 expands on existing anti-angiogenic therapies by ablating key compensatory and resistance mechanisms to bevacizumab, CTX-471 restores local immune reactivity through activation of costimulatory immune mediators. Combination of these two agents may further impair tumor proliferation through synergistic effects on the tumor microenvironment

NCT Number	NCT07392957
Lead Sponsor	Washington University School of Medicine Collaborators: Compass Therapeutics
Conditions	Glioblastoma
Enrollment	54 participants
Start Date	2026-06-16
Primary Completion	2029-06-30 (estimated)
Study Completion	2031-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-22